Clinical Trials
32 trialsAllogeneic γ9δ2 T Cells Treatment of Recurrent Hematologic Tumors
Anhui Provincial Hospital
GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
The First Affiliated Hospital of Soochow University
EBV CAR-T Cells for Nasopharyngeal Carcinoma
The Affiliated Hospital of Xuzhou Medical University
BGT007 Cell Treatment of Nasopharyngeal Carcinoma
The Affiliated Hospital of Xuzhou Medical University
T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma
Karolinska University Hospital
Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL
The First Affiliated Hospital with Nanjing Medical University
Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Fred Hutchinson Cancer Center
MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin
GC Cell Corporation
NK Cells in Cord Blood Transplantation
M.D. Anderson Cancer Center
a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients
Institute of Hematology & Blood Diseases Hospital, China
Investigator Initiated Phase 1 Study of TBI-1301
Mie University
PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
Chinese PLA General Hospital
Reduced Intensity Conditioning (RIC) Regimen and Post-transplant Cyclophosphamide in Haploidentical Bone Marrow Transplantation in in Patients With Poor Prognosis Lymphomas
Istituto Clinico Humanitas
Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors
Ann & Robert H Lurie Children's Hospital of Chicago
Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases
National Cancer Institute (NCI)
Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders
National Cancer Institute (NCI)
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia
National Cancer Institute (NCI)
AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy
Changhai Hospital
Vaccine Therapy With or Without Fludarabine in Treating Patients With Stage IV Kidney Cancer
National Cancer Institute (NCI)
Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes in Treating Patients With Progressive, Relapsed, or Refractory Hodgkin's Lymphoma
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell Lymphoma
National Cancer Institute (NCI)
Donor Umbilical Cord Blood Transplant After Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease
National Cancer Institute (NCI)
Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma
National Cancer Institute (NCI)
T&B Depletion Non Malignant
Bambino Gesù Hospital and Research Institute
Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma
Technical University of Munich
FAD
Fudan University
Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders
National Cancer Institute (NCI)
HD-MCL2003
Heidelberg University
Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) With Fludarabine, Busulfan, and Total Body Irradiation (TBI)
Samsung Medical Center
Chlorambucil in Treating Patients With Advanced Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)